Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MRT-8102

Other · developed by Monte Rosa Therapeutics

Phase 1 Most advanced trial
GLUE Developer
1 Registered trials

What is MRT-8102?

MRT-8102 is an investigational drug studied in Healthy Volunteers, Elevated CRP.

At a glance

Drug type
Other
Therapy area
Immunology
Developer
Monte Rosa Therapeutics, Inc (GLUE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07119125 Phase 1 Healthy Volunteers Active not recruiting GLUE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Elevated CRPHealthy Volunteers

More from Monte Rosa Therapeutics

MRT-2359 Phase 1/2 MRT-6160 Phase 1

Follow GLUE, the company behind MRT-8102

See GLUE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GLUE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.